 HOLON, Israel, June 29, 2021 PRNewswire -- Compugen Ltd. Nasdaq: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of additional research supporting the differentiation of PVRIG from other immune checkpoint inhibitors. 